Article
Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.
Clinical lung cancer - 1 Jan 2011
Masago Katsuhiro, Fujita Shiro, Togashi Yosuke, Kim Young Hak, Hatachi Yukimasa, Fukuhara Akiko, Nagai Hiroki, Sakamori Yuichi, Mio Tadashi, Mishima Michiaki
Abstract excerpt
BACKGROUND: The aim of this study was to analyze the factors independent of epidermal growth factor (EGFR) gene mutations that affect the progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) after gefitinib therapy. PATIENTS AND METHODS: Eighty patients with advanced NSCLC between January 2003 and April 2010 at Kyoto University Hospital were analyzed for EGFR somatic...
Topics
- Age Factors
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- ErbB Receptors
- Female
- Gefitinib
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms
- Male